With an ongoing threat posed by circulating zoonotic strains, new strategies are required to 8 prepare for the next emergent coronavirus (CoV). Previously, groups had targeted conserved 9 coronavirus proteins as a strategy to generate live-attenuated vaccine strains against current 10 and future CoVs. With this in mind, we explored whether manipulation of CoV NSP16, a 11 conserved 2'O methyltransferase (MTase), could provide a broad attenuation platform against 12 future emergent strains. Using the SARS-CoV mouse model, a NSP16 mutant vaccine was 13 evaluated for protection from heterologous challenge, efficacy in the aging host, and potential 14 for reversion to pathogenesis. Despite some success, concerns for virulence in the aged and 15 potential for reversion makes targeting NSP16 alone an untenable approach. However, 16 combining a 2'O MTase mutation with a previously described CoV fidelity mutant produced a 17 vaccine strain capable of protection from heterologous virus challenge, efficacy in aged mice, 18 and no evidence for reversion. Together, the results indicate that targeting the CoV 2'O MTase 19 in parallel with other conserved attenuating mutations may provide a platform strategy for 20 rapidly generating live-attenuated coronavirus vaccines.
Significance

22
Emergent coronaviruses remain a significant threat to global public health and rapid response 23 vaccine platforms are needed to stem future outbreaks. However, failure of many previous CoV 24 vaccine formulations has clearly highlighted the need to test efficacy under different conditions 25 and especially in vulnerable populations like the aged and immune-compromised. This study 26 illustrates that despite success in young models, the NSP16 mutant carries too much risk for 27 pathogenesis and reversion in vulnerable models to be used as a stand-alone vaccine strategy.
28
Importantly, the NSP16 mutation can be paired with other attenuating approaches to provide 29 robust protection from heterologous challenge and in vulnerable populations. Coupled with 30 increased safety and reduced pathogenesis, the study highlights the potential for NSP16 31 attenuation as a major component of future live-attenuated coronavirus vaccines.
32
Introduction
33
The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) at the 34 beginning of the 21st century signaled a new era for emergent viral disease (1). Since then, 35 dozens of viruses have emerged from animal populations to produce significant outbreaks in 36 humans and transfer of zoonotic pathogens remains a major threat to global public health (2). A 37 decade after SARS-CoV, infections with Middle East respiratory syndrome coronavirus (MERS-38 CoV) continue with periodic reintroductions still occurring six years after its initial discovery (3).
39
Coupled with recently discovered SARS-and MERS-like coronaviruses circulating in animal 40 populations, the threat of a coronavirus fueled outbreak remains far from remote (4). With this 41 in mind, strategies must be developed to rapidly respond to a potential CoV emergence or 42 reemergence event.
43
While the SARS-and to a lesser extent the MERS-CoV outbreaks have been mostly 44 contained, this limitation has been primarily due to effective public health measures and the 45 delayed transmissibility of the viruses until after symptomatic disease (5). Standard antiviral 46 treatments with type I IFN or traditional nucleoside analogs like ribavirin have shown minimal 47 success against either epidemic strain (6). While several antibodies have been designed 48 against SARS-and MERS-CoV, their efficacy has been found to be strain specific and may offer 49 minimal protection against heterologous or unrelated coronaviruses, especially under 50 therapeutic conditions (4, 7). Other drugs, targeting conserved CoV activities, have had either 51 marginal efficacy in vivo or offer only a small window for treatment during early infection (8, 9) .
52
Similar to other viral infections, the most effective treatment for coronaviruses is prevention via 53 vaccination.
54
In the context of both the SARS-and MERS-CoV outbreaks, a wealth of vaccine 55 strategies have been developed and examined (10, 11) . Many have utilized sub-unit based 56 approaches; others have used virus like particles or other vector systems to induce immunity.
57
While less desirable for both commercial and safety reasons, a number of live attenuated 58
Results
85
Previous live-attenuated coronavirus platforms had taken advantage of the need and 86 conservation of NSP14 exonuclease (ExoN) and the coronavirus envelope (E) proteins (16, 21) .
87
Similar to ExoN, the NSP16 2'O MTase has significant homology across the coronavirus family, 88 more than CoV envelope proteins ( Fig. 1A) . Importantly, the critical KDKE enzymatic motif is 89 highly conserved allowing predictable disruption of the 2'O MTase function (22) . Unlike ExoN 90 and E viral mutants, dNSP16 viruses have already been shown to attenuate infection of several 91 coronavirus strains including 22) . In addition, for both SARS-and MERS-CoV, 92 the NSP16 mutant viruses induce robust protection following lethal homologous challenge in 93 vivo (19, 20) . However, despite proof of concept studies, several questions about the efficacy of 94 the NSP16 vaccine remain. With the absence of replication attenuation, it is especially important 95 to consider the NSP16 vaccine platform in the context of the overall host response. In addition, 96 evaluation of heterologous challenge, aged models of disease, and the potential for reversion 97 represent critical factors that must be examined prior to further pursuit as a live-attenuated 98 vaccine platform.
99
Early host response to SARS-CoV NSP16 mutant equivalent to wild-type infection.
100
Unlike the ExoN and E protein mutants, dNSP16 coronaviruses demonstrate no significant 101 attenuation in terms of viral replication in vitro except in the context of type I IFN pretreatment 102 (19) . Similarly, in vivo characterizations found no deficit in viral replication at early times (days 1 103 and 2), but a marked attenuation at late times post infection (19, 20) . These results suggest that 104 the early portions of dNSP16 infection are equivalent to wild-type virus infection. To further 105 explore this question, we utilized a systems biology approach to compare wild-type and dNSP16 106 mutant in 20-week old C57BL/6 mice. In this model, mice infected with the mouse-adapted 107 SARS-CoV induce severe weight loss, fail to recover, and several succumb to infection ( Fig.   108   1B) . Notably, while the SARS NSP16 mutant induces weight loss, mice recover from infection 109 diverging from wild-type infection 3 days post infection. Examining viral replication, the NSP16 110 mutant has no discernable attenuation at days 1 or 2 (Fig. 1C) ; however, at day 4, a 100-fold 111 reduction in replication is observed in the lungs of dNSP16 infected mice that corresponds with 112 the kinetics of interferon stimulated gene (ISG) expression. Importantly, the global host 113 expression response models the same trend. PCA plots of total RNA expression finds that wild-114 type and mutant virus profiles cluster together at days 1 and 2 ( Fig. 1D) . At later times, similar 115 to weight loss and viral replication, dNSP16 diverges from WT, suggesting that only at late times 
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With the continued circulation of SARS-and MERS-like viruses in animal populations worldwide 124 (4), vaccine approaches must consider exposure to and protection from related, heterologous 125 coronavirus strains. Utilizing a chimeric mouse adapted SARS-CoV strain incorporating the 126 spike of SHC014-CoV (7), an antigenically distant group 2B coronavirus circulating in Chinese 127 horseshoe bat populations, we evaluated the efficacy of the SARS-CoV dNSP16 in protecting 128 from heterologous CoV challenge. BALB/c mice were vaccinated with 10 5 PFU of SARS 129 dNSP16, monitored for 28 days, and subsequently challenged with the chimeric strain following vaccination ( Fig. 2D) . Together, the data indicate that a live-attenuated NSP16 137 vaccine has sufficient capacity to protect from heterologous CoV challenge in young mice.
138
Low dose dNSP16 vaccination provides protection to aged mice.
139
With high rates of mortality, aged populations represent a vulnerable group in need of effective 140 vaccines to coronaviruses (23). However, previous work has shown that SARS-CoV vaccines 141 have had mixed success in aged populations (14, 24) . To explore efficacy of dNSP16 in a 142 senescent model, we examined infection of 12-month old BALB/c mice which recapitulates the 143 age-dependent susceptibility observed in humans. Following infection with 10 5 PFU of wild-type 144 or dNSP16, the 2'O MTase mutant was equal to WT SARS-CoV infection in terms of weight loss 145 and lethality ( Fig. 3A & B) . While this dose protected young mice from heterologous challenge, 146 significant pathogenesis occurred in the aged mice despite attenuation in viral replication at day 147 4 ( Fig. 3C) . Together, the data indicates that despite replication attenuation, the dNSP16 148 mutant harbors pathogenic potential at high doses in aged mice.
149
While capable of inducing lethal disease, the utilized dose of the dNSP16 mutant 150 represents a significant increase over the LD 50 of WT SARS-CoV in aged mice (25). Therefore,
151
we challenged 12-month old BALB/c mice with 100 PFU of WT or dNSP16 and evaluated 152 pathogenesis. Following low dose challenge, dNSP16 infected aged mice had reduced disease 153 as compared to control in terms of weight loss and survival ( Fig. 3D & E) . The reduced 154 pathogenesis corresponded to reduced viral replication at both days 2 and 4, recapitulating in 155 vivo attenuation previously observed in young animals ( Fig. 3F) (19) . Notably, dNSP16 infection 156 resulted in only marginal disease in terms of weight loss (<5%) and respiratory parameters, 157 including airway resistance (PenH, Fig. 3G ) and mid-tidal expiratory flow (EF50, Fig. 3H ). To 158 explore protection, 12-month old mice were vaccinated with 100 PFU of dNSP16 and 159 subsequently challenged 28 days later with a lethal dose of wild-type SARS-CoV MA15 (10 5 160 PFU). Both, in terms of weight loss and survival ( Fig. 4A & B) , vaccination with dNSP16 161 provided robust protection from lethal disease and pathogenesis; this protection corresponded 162 with the absence of detectable viral replication at both days 2 and 4 ( Fig. 4I) . Together, the 163 results indicate that while the dNSP16 mutant harbors some risk of pathogenicity at high doses, 164 it can also provide aged mice with robust protection from lethal challenge.
165
NSP16 mutant reverts in immune-compromised model.
166
Despite some important caveats, the dNSP16 mutant has demonstrated efficacy as a vaccine 167 following both, heterologous challenge and in aged models of SARS-CoV disease. However, 168 reversion and adaptation of a live attenuated strain represents a significant concern for its use in 
193
With this in mind, we set forth to evaluate a SARS-CoV mutant lacking both NSP16 activity as 194 well as CoV fidelity (dNSP16/ExoN). Compared to WT or the original dNSP16 mutant, the 195 SARS dNSP16/ExoN virus had replication attenuation in its initial stock titers as well as in a 196 multistep growth curve (Fig. 6A) ; however, the double mutant had equivalent replication to the 197 SARS ExoN mutant indicating no additional replication attenuation in vitro. In vivo, the SARS 198 dNSP16/ExoN mutant also had significant attenuation relative to WT control virus. Following 199 infection of 10-week old BALB/c, dNSP16/ExoN produced no weight loss with significant 200 changes compared to WT infection as early as day 2 post infection ( Fig. 6B) . Similarly, viral 201 replication was significantly attenuated at both days 2 and 4 ( Fig. 6C) . Finally, no signs of 202 hemorrhage were observed following infection with the double mutant ( Fig. 6D) . Together, the 203 data is consistent with the level of attenuation observed for the original SARS-CoV ExoN mutant 204 and suggested that the dNSP16/ExoN mutant may serve as a possible live attenuated vaccine.
205
With vaccination in mind, we explored the dNSP16/ExoN mutant in the context of (Fig. 6F) . Importantly, sera from dNSP16/ExoN vaccinated mice was capable of 215 neutralizing both WT SARS-CoV as well as chimeric spike virus (Fig. 6H) . While not equivalent 216 to neutralization induced by the dNSP16 mutant (Fig. 2) , the results indicate that the double 217 mutant vaccine provided robust protection from both homologous and heterologous challenge.
218
Double mutant protects aged mice from lethal disease.
219
Having demonstrated efficacy in young mice and against heterologous challenge, we next 220 explored the SARS-CoV dNSP16/ExoN mutant in the context of an aging host. Twelve-month 221 old BALB/c mice were challenged with 100 PFU of WT SARS-CoV (MA15) or the dNSP16/ExoN 222 mutant. In terms of both weight loss ( Fig. 7A) and lethality (Fig. 7B) , the dNSP16/ExoN mutant 223 was highly attenuated compared to the lethal WT infection. Similar to the young mouse 224 challenge, the dNSP16/ExoN mutant had attenuated replication at days 2 and 4 post infection 225 ( Fig. 7C) and no signs of hemorrhage (Fig. 7D) . Importantly, mice vaccinated with 226 dNSP16/ExoN were completely protected from lethal SARS-CoV challenge. Both weight loss 227 and survival showed complete protection in the vaccinated animals ( Fig. 7E) ; in contrast, WT 228 infected mice had significant weight loss and 2/3 succumbed to infection by day 4. Titers in the 229 lung demonstrated no viral replication in vaccinated aged mice; in contrast, the lone surviving 230 mock-vaccinated mice had significant titer within the lung (Fig. 7F) . Together, the data 231 demonstrated the utility and efficacy of the dNSP16/ExoN mutant as a live attenuated vaccine in 232 aged models of disease.
233
SARS-CoV dNSP16/ExoN cleared from immune compromised mice.
234
Having addressed both heterologous challenge and efficacy in aged models, we next examined 235 the dNSP16/ExoN mutation for reversion potential. Similar to the original dNSP16 mutant, 236 dNSP16/ExoN showed no significant disease in RAG -/mice during acute infection. After 30 237 days, mice were euthanized, lung tissue harvested, homogenized, clarified, and used to infect 238 10-week old BALB/c mice. Contrasting dNSP16 (Fig. 4) , reinfection from lung homogenate of 239 RAG -/mice infected with the double mutant failed to induce any significant disease in terms of 240 weight loss or lethality upon acute infection (Fig. 7G) . Examination of input viral titer revealed 241 the absence of detectable virus in all five RAG -/mice infected with the dNSP16/ExoN mutant 242 (Fig. 7H) . The results indicate that following in vivo replication for 30 days, the dNSP16/ExoN 243 mutant failed to revert to a virulent form. In addition, the results suggest that the double mutant 244 could be cleared in immune compromised mice without the need for traditional adaptive 245 immunity. Together, the data argue that the dNSP16/ExoN mutant is unlikely to revert even in 246 immune compromised models and fulfills a key consideration for a live-attenuated coronavirus 247 platform.
249
Discussion
250
The threat of zoonotic coronaviruses stems not only from their potential for emergence, 251 but also from the lack of effective strategies to combat epidemic coronavirus disease. While 
269
the absence of replication defects for NSP16 mutants offers both utility and risk. While capable 270 of inducing robust immunity, even to heterologous challenge, the NSP16 mutant virus retains 271 virulence in aged animals at high doses. Importantly, the augmented replication potentially 272 contributes to its ability to revert to virulence in immunocompromised models. Together, the 273 results suggest that the robust immunity induced by NSP16 mutants in young mice comes at the 274 cost of higher virulence and the potential for reversion, thus limiting its use to only dire 275 situations.
276
Given the risk associated with NSP16 mutation as a single target attenuation platform,
277
we evaluated ways to increase safety without sacrificing vaccine efficacy. We first considered 
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In pursuing vaccine platforms for coronaviruses, our data argues a multiple-mechanism, 293 attenuation approach may be the fastest route to an effective, safe vaccine in the context of an 294 outbreak. In this work, the absence of replication deficits permitted pairing of the NSP16 295 mutation with the less fit SARS ExoN mutant; alternatively, a SARS E protein mutant could also 296 have been selected and has previously been shown to work in combination with another 297 attenuating mutation in SARS NSP1 (17). However, the appeal of targeting NSP16 revolves 298 around the lack of replication attenuation, complete conservation of the required KDKE motif, 299 and the vaccine protection offered by a viable MERS-CoV NSP16 mutant. These factors, absent 300 from both ExoN and E protein platforms, make targeting NSP16 a priority approach for live-301 attenuated vaccines. Importantly, translation of vaccine efficacy to heterologous challenge, 302 vulnerable aged populations, and lack of reversion to virulence distinguish the NSP16 303 combination platform from other approaches tried to date. Cells & Viruses. Wild-type, mutant, and mouse adapted SARS-CoV were previously described 320 (27, 28) and cultured on Vero 81 cells, grown in DMEM or OptiMEM (Gibco, CA) and 5% Fetal
321
Clone Serum (Hyclone, South Logan, UT) along with antibiotic/antimycotic (Gibco, Carlsbad, 322 CA). Growth curves in Vero cells were performed as previously described with multiple samples 323 (n ≥ 3) examined at each time point (9, 31). Briefly, cells were washed with PBS, and 324 inoculated with virus or mock diluted in PBS for 40 minutes at 37 °C. Following inoculation, cells 325 were washed 3 times, and fresh media added to signify time 0 hr. Samples were harvested at 326 the described time points. All virus cultivation was performed in a BSL3 laboratory with 327 redundant fans in Biosafety Cabinets as described previously by our group (32, 33) . All 
332
(MA15) infectious clone as previously described (25, 29) . For NSP16/ExoN mutant construction, 333 we utilized the constructs previously generated for individual NSP16 (19) and NSP14 ExoN (16) 334 mutants located on different fragments (D & E respectively). Thereafter, plasmids containing 335 wild-type and mutant SARS-CoV genome fragments were amplified, excised, ligated, and 336 purified. In vitro transcription reactions were then preformed to synthesize full-length genomic 337 RNA, which was transfected into Vero E6 cells. The media from transfected cells were 338 harvested and served as seed stocks for subsequent experiments. Viral mutants were 339 confirmed by sequence analysis prior to use. Synthetic construction of mutants of NSP16 and 340 NSP14 were approved by the University of North Carolina Institutional Biosafety Committee.
341
RNA isolation, microarray processing and identification of differential expression. RNA 342 isolation and microarray processing, quality control, and normalization from whole lung 343 homogenate was carried out as previously described (30). Differential expression (DE) was 344 determined by comparing virus-infected replicates to time-matched mock replicates. Criteria for 345 DE in determining the consensus ISG list were an absolute Log 2 fold change of >1.5 and a false 346 discovery rate (FDR)-adjusted P value of <0.05 for a given time point. 
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Virus Neutralization Assays. Plaque reduction neutralization titer assays were performed with 372 previously characterized antibodies against SARS-CoV as previously described (32). Briefly, 373 neutralizing antibodies or serum were serially diluted 2-fold and incubated with 100 PFU of the 374 different virus strains for 1 h at 37 °C. The virus and antibodies were then added to a 6-well 375 plate with 5 × 10 5 Vero E6 cells/well with n  2. After an 1-h incubation at 37 °C, cells were 376 overlaid with 3 ml of 0.8% agarose in media. Plates were incubated for 2 days at 37 °C and then 
